1. Pillai S, Gopalan V, Smith RA, Lam AK. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. Crit Rev Oncol Hematol 2016;100:190-208.
[CROSSREF] [PUBMED]
2. Crona J, Tajeb D, Pacak K. New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr Rev 2017;38:489-515.
[CROSSREF] [PUBMED] [PMC]
3. Toledo RA. Genetics of pheochromocytomas and paragangliomas: an overview on the recently implicated genes MERTK, MET, fibroblast growth factor receptor 1, and H3F3A. Endocrinol Metab Clin North Am 2017;46:459-89.
[CROSSREF] [PUBMED]
4. Alrezk R, Suarez A, Tena I, Pacak K. Update of pheochromocytoma syndromes: genetics, biochemical evaluation, and imaging. Front Endocrinol (Lausanne) 2018;9:515.
[CROSSREF] [PUBMED] [PMC]
5. Koopman K, Gaal J, de Krijger RR. Pheochromocytomas and paragangliomas: new developments with regard to classification, genetics, and cell of origin. Cancers (Basel) 2019;11:1070.
[CROSSREF] [PUBMED] [PMC]
6. Neumann HP, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med 2019;381:552-65.
[CROSSREF] [PUBMED]
7. Antonio K, Valdez MM, Mercado-Asis L, Tajeb D, Pacak K. Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. Gland Surg 2020;9:105-23.
[CROSSREF] [PUBMED] [PMC]
8. Benn DE, Robinson BG, Clifton-Bligh RJ. 15 Years of paraganglioma: clinical manifestations of paraganglioma syndromes types 1-5. Endocr Relat Cancer 2015;22:T91-103.
[CROSSREF] [PUBMED] [PMC]
9. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014;99:1915-42.
[CROSSREF] [PUBMED]
10. Nolting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, Grossman A, et al. Current management of pheochromocytoma/paraganglioma: a guide for the practicing clinician in the era of precision medicine. Cancers (Basel) 2019;11:1505.
[CROSSREF] [PUBMED] [PMC]
11. Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2014;21:405-14.
[CROSSREF] [PUBMED]
12. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002;26:551-66.
[CROSSREF] [PUBMED]
13. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-24.
[CROSSREF] [PUBMED] [PMC]
14. Evenepoel L, Papathomas TG, Krol N, Korpershoek E, de Krijger RR, Persu A, et al. Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations. Genet Med 2015;17:610-20.
[CROSSREF] [PUBMED]
15. Bannon AE, Kent J, Forquer I, Town A, Klug LR, McCann K, et al. Biochemical, molecular, and clinical characterization of succinate dehydrogenase subunit a variants of unknown significance. Clin Cancer Res 2017;23:6733-43.
[CROSSREF] [PUBMED] [PMC]
16. Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, et al. Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention. JAMA Oncol 2017;3:1204-12.
[CROSSREF] [PUBMED] [PMC]
17. Lefebvre S, Borson-Chazot F, Boutry-Kryza N, Wion N, Schillo F, Peix JL, et al. Screening of mutations in genes that predispose to hereditary paragangliomas and pheochromocytomas. Horm Metab Res 2012;44:334-8.
[CROSSREF] [PUBMED]
18. Ben Aim L, Pigny P, Castro-Vega LJ, Buffet A, Amar L, Bertherat J, et al. Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. J Med Genet 2019;56:513-20.
[CROSSREF] [PUBMED]
19. Bauters C, Vantyghem MC, Leteurtre E, Odou MF, Mouton C, Porchet N, et al. Hereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes. J Med Genet 2003;40:e75.
[CROSSREF] [PUBMED] [PMC]
20. Espana A, Ornilla E, Zarate R, Gil-Bazo I, Briones P. Myopathy in hereditary leiomyomatosis and renal cell cancer in an extended family. Br J Dermatol 2015;172:1442-5.
[CROSSREF] [PUBMED]
21. Van der Tuin K, Mensenkamp AR, Tops CM, Corssmit EP, Dinjens WN, van de Horst-Schrivers AN, et al. Clinical aspects of SDHA-related pheochromocytoma and paraganglioma: a nationwide study. J Clin Endocrinol Metab 2018;103:438-45.
[CROSSREF] [PUBMED]
22. Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 2008;22:884-93.
[CROSSREF] [PUBMED] [PMC]
23. Welander J, Andreasson A, Juhlin CC, Wiseman RW, Backdahl M, Hoog A, et al. Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2014;99:E1352-60.
[CROSSREF] [PUBMED] [PMC]
24. Pillai S, Gopalan V, Lo CY, Liew V, Smith RA, Lam AK. Silent genetic alterations identified by targeted next-generation sequencing in pheochromocytoma/paraganglioma: a clinicopathological correlations. Exp Mol Pathol 2017;102:41-6.
[CROSSREF] [PUBMED]
25. Remacha L, Curras-Freixes M, Torres-Ruiz R, Schiavi F, Torres-Perez R, Calsina B, et al. Gain-of-function mutations in DNMT3A in patients with paraganglioma. Genet Med 2018;20:1644-51.
[CROSSREF] [PUBMED]
26. Schrader KA, Cheng DT, Joseph V, Prasad M, Walsh M, Zehir A, et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol 2016;2:104-11.
[CROSSREF] [PUBMED] [PMC]
27. Barak F, Shiri-Svredlov R, Bruchim-Bar Sade R, Kruglikova A, Friedman E, Ben-Dor D, et al. Adrenal tumors in BRCA1/BRCA2 mutation carriers. Am J Med Genet 2001;98:277-9.
[CROSSREF] [PUBMED]
28. Song MK, Kim GB, Bae EJ, Lee YA, Kim HY, Min SK, et al. Pheochromocytoma and paraganglioma in Fontan patients: common more than expected. Congenit Heart Dis 2018;13:608-16.
[CROSSREF] [PUBMED]
29. Wesley NA, Wachnowsky C, Fidai I, Cowan JA. Understanding the molecular basis for multiple mitochondrial dysfunctions syndrome 1 (MMDS1): impact of a disease-causing Gly189Arg substitution on NFU1. FEBS J 2017;284:3838-48.
[CROSSREF] [PUBMED] [PMC]
30. Lill R, Hoffmann B, Molik S, Pierik AJ, Rietzschel N, Stehling O, et al. The role of mitochondria in cellular iron-sulfur protein biogenesis and iron metabolism. Biochim Biophys Acta 2012;1823:1491-508.
[CROSSREF] [PUBMED]
31. Van Vranken JG, Na U, Winge DR, Rutter J. Protein-mediated assembly of succinate dehydrogenase and its cofactors. Crit Rev Biochem Mol Biol 2015;50:168-80.
[CROSSREF] [PUBMED]
32. Fatkin D, Johnson R. Variants of uncertain significance and “missing pathogenicity”. J Am Heart Assoc 2020;9:e015588.
[CROSSREF] [PUBMED] [PMC]